Ebola Vaccine co-developed by NIH Well Tolerated by 1,500 adults in West Africa

Results from a large clinical trial in Liberia showed that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses that last for at least one year. One of the two vaccine candidate was co-developed by National Institute of Allergy and Infectious Diseases (NIAID)'s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK).

The trial is being conducted by a U.S.-Liberia clinical research collaboration known as the Partnership for Research on Ebola Virus in Liberia (PREVAIL), established in 2014 in response to the request from the Liberian Minister of Health to the U.S. Secretary of Health and Human Services. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and involves scientists and clinicians from Liberia and the United States. PREVAIL conducts collaborative biomedical research in accordance with best practices, to advance science, strengthen health policy and practice, and improve the health of people in Liberia and around the world.

The findings were published in the October 12 issue of the New England Journal of Medicine. Click here to view the abstract.

To find out more about the NIAID VRC, please visit: https://www.niaid.nih.gov/about/vrc

To view NIH OTT ebola-related technologies available for licenisng, please visit: https://www.ott.nih.gov/opportunities?body_value=ebola